

### Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

#### Listing of Claims

Claims 1-7. Canceled without prejudice.

Claims 8-18. Previously canceled without prejudice.

19. (Currently Amended) A method of treating or preventing an affective disorder which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, wherein the affective disorder is depression, attention deficit disorder with hyperactivity, attention deficit hyperactivity disorder, obesity, nicotine addiction, or cocaine addiction, and wherein the optically pure bupropion metabolite is racemic 2-(tert-butylamino)-1-(3-chlorophenyl)-propan-1-ol; optically pure (R,R)-2-(tert-butylamino)-1-(3-chlorophenyl)-propan-1-ol; optically pure (S,R)-2-(tert-butylamino)-1-(3-chlorophenyl)-propan-1-ol; optically pure (S,S)-2-(tert-butylamino)-1-(3-chlorophenyl)-propan-1-ol; optically pure (R,S)-2-(tert-butylamino)-1-(3-chlorophenyl)-propan-1-ol; racemic 1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone; optically pure (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone; or optically pure (S)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone.

Claims 20-22. Canceled without prejudice.

23. (Original) The method of claim 19 wherein adverse effects associated with the administration of racemic bupropion are reduced or avoided.

Claims 24-126. Canceled without prejudice.

127. (New) A method of treating or preventing an affective disorder which comprises administering to a patient in need of such treatment or prevention a

therapeutically or prophylactically effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, wherein the bupropion metabolite, or pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, is adjunctively administered with a therapeutically or prophylactically effective amount of a second pharmacologically active compound.

128. (New) The method of claim 127, wherein the bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethylmorphinol, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

129. (New) The method of claim 127, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction, depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

130. (New) The method of claim 128, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction, depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

131. (New) The method of claim 127, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT<sub>3</sub> inhibitor, or nicotine.

132. (New) The method of claim 128, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT<sub>3</sub> inhibitor, or nicotine.